VREOF (Vireo Growth) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Vireo Growth is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Vireo Growth's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vireo Growth's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Vireo Growth's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Vireo Growth (OTCPK:VREOF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Vireo Growth Risk Assessment Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Vireo Growth Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

0ZF:Germany VREO:Canada

Address

207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402

Website

https://www.vireogrowth.com

Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs. The company's operating results in one business segment: the cultivation, production, and sale of cannabis.

Executives

Chicago Atlantic Credit Opportunities, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc	10 percent owner	420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen	director	207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio	officer: Chief Operating Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa	director, officer: Chief Administrative Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters	officer: EVP of Retail	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder	officer: General Counsel & CCO	3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller	officer: Chief Financial Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402